Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Charles D. Giamberardino"'
Autor:
Julia R. Palmucci, Blake E. Sells, Charles D. Giamberardino, Dena L. Toffaletti, Baodi Dai, Yohannes G. Asfaw, Laura G. Dubois, Zhong Li, Barbara Theriot, Wiley A. Schell, William Hope, Jennifer L. Tenor, John R. Perfect
Publikováno v:
mBio, Vol 15, Iss 5 (2024)
ABSTRACTInvasive fungal infections are a significant public health concern, with mortality rates ranging from 20% to 85% despite current treatments. Therefore, we examined whether a ketogenic diet could serve as a successful treatment intervention in
Externí odkaz:
https://doaj.org/article/1c4d26c9463d44078161728fc5c59925
Autor:
Charles D. Giamberardino, Wiley A. Schell, Jennifer L. Tenor, Dena L. Toffaletti, John R. Perfect
Publikováno v:
Journal of Fungi, Vol 10, Iss 8, p 520 (2024)
Cryptococcal meningitis (CM) causes significant global morbidity and mortality. Current therapeutic strategies rely on deoxycholated or liposomal forms of the polyene amphotericin B. Nystatin is also a polyene with broad-spectrum antimicrobial activi
Externí odkaz:
https://doaj.org/article/97071ee09cf54f59b5a21e0ffb80f0f2
Autor:
Charles D. Giamberardino, Wiley A. Schell, Jennifer L. Tenor, Dena L. Toffaletti, Julia R. Palmucci, Choiselle Marius, Jane-Valeriane K. Boua, Quinlyn Soltow, Robert Mansbach, M. Arthur Moseley, J. Will Thompson, Laura G. Dubois, William Hope, John R. Perfect, Karen Joy Shaw
Publikováno v:
mBio, Vol 13, Iss 6 (2022)
ABSTRACT Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 inhibitor APX2039, in a mouse model of CM. Here, we investiga
Externí odkaz:
https://doaj.org/article/12c94fc2bb48423287573f9192ce65ce
Autor:
Charles D Giamberardino, Jennifer L Tenor, Dena Toffaletti, Julia R Palmucci, Don Cilla, William Hope, John R Perfect
Publikováno v:
Open Forum Infectious Diseases. 9
Background Cryptococcal meningitis (CM) is a fungal disease with significant global morbidity and mortality. There are multiple new therapies being developed to improve the current regimens involving amphotericin B, flucytosine, and fluconazole. ATI-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6205318d21ba5d74a796be2a536e51f4
https://doi.org/10.1093/ofid/ofac492.657
https://doi.org/10.1093/ofid/ofac492.657
Autor:
Julia A Messina, Charles D Giamberardino, Jennifer Tenor, Dena Toffaletti, Wiley Schell, Michail Lionakis, John R Perfect
Publikováno v:
Open Forum Infectious Diseases. 8:S458-S458
Background Patients receiving the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib have an increased likelihood of systemic and central nervous system (CNS) fungal infections. Previous work has shown that BTK knockout (KO) mice have more severe A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92ffcb983c128d84324569ad9e370b1f
https://doi.org/10.1093/ofid/ofab466.914
https://doi.org/10.1093/ofid/ofab466.914